Martin Štěrba Selected Research

Dexrazoxane (Zinecard)

1/2022	Primary prevention of chronic anthracycline cardiotoxicity with ACE inhibitor is temporarily effective in rabbits, but benefits wane in post-treatment follow-up.
11/2021	Clinically Translatable Prevention of Anthracycline Cardiotoxicity by Dexrazoxane Is Mediated by Topoisomerase II Beta and Not Metal Chelation.
1/2021	Structure-Activity Relationship Study of Dexrazoxane Analogues Reveals ICRF-193 as the Most Potent Bisdioxopiperazine against Anthracycline Toxicity to Cardiomyocytes Due to Its Strong Topoisomerase IIβ Interactions.
1/2021	Development of water-soluble prodrugs of the bisdioxopiperazine topoisomerase IIβ inhibitor ICRF-193 as potential cardioprotective agents against anthracycline cardiotoxicity.
1/2020	Investigation of Structure-Activity Relationships of Dexrazoxane Analogs Reveals Topoisomerase IIβ Interaction as a Prerequisite for Effective Protection against Anthracycline Cardiotoxicity.
1/2018	Pharmacokinetics of the Cardioprotective Drug Dexrazoxane and Its Active Metabolite ADR-925 with Focus on Cardiomyocytes and the Heart.
2/2016	Cardioprotective effects of inorganic nitrate/nitrite in chronic anthracycline cardiotoxicity: Comparison with dexrazoxane.
9/2013	Early and delayed cardioprotective intervention with dexrazoxane each show different potential for prevention of chronic anthracycline cardiotoxicity in rabbits.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Martin Štěrba Research Topics

Disease

12	Cardiotoxicity 01/2022 - 07/2007
5	Heart Failure 11/2021 - 02/2016
2	Neoplasms (Cancer) 11/2020 - 11/2016
2	Cardiomyopathies (Cardiomyopathy) 01/2020 - 07/2007
1	Cardiovascular Diseases (Cardiovascular Disease) 11/2020
1	Myocardial Ischemia (Ischemic Heart Diseases) 02/2016
1	Reperfusion Injury 02/2016
1	Left Ventricular Dysfunction 01/2014

Drug/Important Bio-Agent (IBA)

13	AnthracyclinesIBA 01/2022 - 07/2007
8	Dexrazoxane (Zinecard)FDA LinkGeneric 01/2022 - 09/2013
7	Daunorubicin (Cerubidine)FDA LinkGeneric 01/2022 - 07/2007
6	Pharmaceutical PreparationsIBA 01/2021 - 07/2007
3	IronIBA 11/2021 - 01/2018
3	ProdrugsIBA 01/2021 - 01/2018
2	Type II DNA Topoisomerases (Topoisomerase II)IBA 01/2022 - 11/2021
2	Cardiotonic Agents (Cardiac Stimulants)IBA 01/2022 - 01/2021
2	MetalsIBA 11/2021 - 01/2020
2	4,4'- (1,2- dimethyl- 1,2- ethanediyl)bis- 2,6- piperazinedioneIBA 01/2021 - 01/2021
2	TroponinIBA 11/2020 - 07/2007
2	Biomarkers (Surrogate Marker)IBA 11/2020 - 07/2007
1	Perindopril FDA LinkGeneric 01/2022
1	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 01/2022
1	Trastuzumab (Herceptin)FDA Link 11/2020
1	Natriuretic PeptidesIBA 11/2020
1	PropaneIBA 01/2020
1	ICRF 198IBA 01/2018
1	3-nitrotyrosineIBA 11/2016
1	Molsidomine (SIN 10)IBA 11/2016
1	NitritesIBA 02/2016
1	NitratesIBA 02/2016
1	Troponin IIBA 07/2007
1	Troponin T (Troponin T1)IBA 07/2007

Therapy/Procedure

2	Drug Therapy (Chemotherapy) 11/2020 - 11/2016
1	Therapeutics 11/2020